{"log_id": 3604710156866667071, "direction": 0, "words_result_num": 44, "words_result": [{"probability": {"variance": 0.001477, "average": 0.98737, "min": 0.771232}, "location": {"width": 751, "top": 156, "height": 26, "left": 283}, "words": "在儿童患者中,利奈唑胺的最大血药浓度(Cmax)和分布容积(Vss)与年龄无关。利奈"}, {"probability": {"variance": 4.7e-05, "average": 0.996558, "min": 0.968959}, "location": {"width": 795, "top": 185, "height": 28, "left": 240}, "words": "唑胺的清除率与年龄相关。除了出生不到一周的新生儿,年龄最小的儿童组,即出生一周后"}, {"probability": {"variance": 5e-05, "average": 0.99676, "min": 0.957032}, "location": {"width": 790, "top": 217, "height": 27, "left": 242}, "words": "至11岁年龄段,与成年人相比,清除速率最快,从而导致了单剂量给药后较低的全身药物"}, {"probability": {"variance": 9e-06, "average": 0.998016, "min": 0.984979}, "location": {"width": 774, "top": 248, "height": 25, "left": 241}, "words": "暴露量(AUC)和较短的半衰期。随着儿童患者年龄的增加,利奈唑胺的清除率逐渐降低"}, {"probability": {"variance": 4.7e-05, "average": 0.99669, "min": 0.96005}, "location": {"width": 795, "top": 279, "height": 27, "left": 240}, "words": "青春期的儿童患者的清除率已与成年患者的相似。与成人相比,在所有不同年龄层的儿童患"}, {"probability": {"variance": 0.002004, "average": 0.990147, "min": 0.749621}, "location": {"width": 575, "top": 310, "height": 26, "left": 242}, "words": "者中观察到清除率与全身药物暴露量(AUC)存在更大的个体差异"}, {"probability": {"variance": 0.000154, "average": 0.99438, "min": 0.929103}, "location": {"width": 754, "top": 339, "height": 27, "left": 283}, "words": "新生儿至11岁的儿童患者每8小时给药一次的日平均AUC值与青少年和成年患者每12"}, {"probability": {"variance": 0.000196, "average": 0.994883, "min": 0.917331}, "location": {"width": 792, "top": 370, "height": 26, "left": 243}, "words": "小时给药一次的日平均AUC值相似。因而,11岁及小于11岁儿童患者的给药剂量应为"}, {"probability": {"variance": 0.00012, "average": 0.996216, "min": 0.939677}, "location": {"width": 755, "top": 400, "height": 26, "left": 245}, "words": "0mg/kg,每8小时一次。12岁及其以上的儿童患者给药剂量为600mg每12小时一次"}, {"probability": {"variance": 6e-06, "average": 0.998672, "min": 0.988058}, "location": {"width": 753, "top": 430, "height": 25, "left": 284}, "words": "出生后不到7天的早产儿(小于34个孕周)的用药方案是依据于9例早产儿的药代动"}, {"probability": {"variance": 5e-05, "average": 0.996137, "min": 0.95994}, "location": {"width": 796, "top": 460, "height": 27, "left": 242}, "words": "力学数据。与足月的新生儿和较大的新生儿相比,大多数早产儿的系统清除率较低,且AUC"}, {"probability": {"variance": 0.000101, "average": 0.996559, "min": 0.935932}, "location": {"width": 794, "top": 490, "height": 28, "left": 242}, "words": "值较高。所以,早产儿的治疗应从10mg/kg,每12小时一次的初始剂量开始。对临床上未"}, {"probability": {"variance": 0.001264, "average": 0.991053, "min": 0.796198}, "location": {"width": 795, "top": 520, "height": 26, "left": 241}, "words": "取得最佳疗效的新生儿可考虑采用10mg/kg,每8小时一次的治疗方案。所有出生7天或以"}, {"probability": {"variance": 0.000144, "average": 0.994419, "min": 0.938669}, "location": {"width": 789, "top": 546, "height": 30, "left": 248}, "words": "上的新生儿应按10mg/kg每8小时的剂量给药(见【药代动力学】一特殊人群、儿童和【用"}, {"probability": {"variance": 0.00021, "average": 0.983911, "min": 0.959674}, "location": {"width": 82, "top": 581, "height": 25, "left": 242}, "words": "法用量】"}, {"probability": {"variance": 0.000373, "average": 0.99212, "min": 0.892965}, "location": {"width": 751, "top": 609, "height": 27, "left": 285}, "words": "在有限的临床经验中,6例儿童患者中的5例(83%,利奈唑胺对其所感染的革兰阳"}, {"probability": {"variance": 0.000189, "average": 0.993268, "min": 0.92639}, "location": {"width": 793, "top": 640, "height": 26, "left": 243}, "words": "性病原体的最低抑菌浓度MC为4μg/mL,经利奈唑胺治疗获得临床痊愈。与成人相比,儿"}, {"probability": {"variance": 0.000236, "average": 0.992898, "min": 0.910503}, "location": {"width": 793, "top": 669, "height": 27, "left": 244}, "words": "童患者间利奈唑胺的清除率和全身药物暴露量(AUC)表现出更大的个体间差异。对未获得最"}, {"probability": {"variance": 9.4e-05, "average": 0.996368, "min": 0.938967}, "location": {"width": 794, "top": 701, "height": 26, "left": 244}, "words": "佳临床疗效的儿童患者,尤其对于利奈唑胺最低抑菌浓度为4μg/mL的病原体,在评价临床"}, {"probability": {"variance": 0.000112, "average": 0.996336, "min": 0.936727}, "location": {"width": 795, "top": 729, "height": 27, "left": 242}, "words": "疗效时,应考虑到患儿较低的全身药物暴露量、感染的部位及其严重程度以及其基础疾病(见"}, {"probability": {"variance": 0.000384, "average": 0.991427, "min": 0.903501}, "location": {"width": 441, "top": 758, "height": 28, "left": 250}, "words": "【药代动力学】一特殊人群、儿童和【用法用量】)"}, {"probability": {"variance": 0.000535, "average": 0.988135, "min": 0.936448}, "location": {"width": 105, "top": 821, "height": 26, "left": 256}, "words": "【老年用药】"}, {"probability": {"variance": 0.005801, "average": 0.985918, "min": 0.504504}, "location": {"width": 752, "top": 849, "height": 26, "left": 287}, "words": "在Ⅲ期对照研究中,2046例患者接受了利奈唑胺治疗,其中589(29%)例为65岁"}, {"probability": {"variance": 0.003024, "average": 0.989054, "min": 0.633489}, "location": {"width": 796, "top": 877, "height": 30, "left": 245}, "words": "或65岁以上的患者;253例(12%)患者年龄大于等于75岁。未见利奈唑胺在这些患者与"}, {"probability": {"variance": 1e-06, "average": 0.999217, "min": 0.997332}, "location": {"width": 346, "top": 910, "height": 27, "left": 246}, "words": "年轻患者之间有安全性和有效性的差异"}, {"probability": {"variance": 2.9e-05, "average": 0.995809, "min": 0.982669}, "location": {"width": 153, "top": 970, "height": 29, "left": 251}, "words": "【药物相互作用】"}, {"probability": {"variance": 4e-06, "average": 0.997317, "min": 0.993016}, "location": {"width": 299, "top": 1002, "height": 25, "left": 249}, "words": "通过细胞色素酶P450代谢的药物"}, {"probability": {"variance": 0.006229, "average": 0.983062, "min": 0.478695}, "location": {"width": 756, "top": 1029, "height": 28, "left": 286}, "words": "在大鼠中,利奈唑胺不是细胞色素酶P450(CYP450)的诱导剂。另外,利奈唑胺不抑"}, {"probability": {"variance": 0.003932, "average": 0.977579, "min": 0.630149}, "location": {"width": 795, "top": 1058, "height": 34, "left": 247}, "words": "制有临床意义的人类细胞色素同工酶(如1A2,2C9;2C19,2D6,2E1和3A4)的活性。所以"}, {"probability": {"variance": 0.00158, "average": 0.990806, "min": 0.743848}, "location": {"width": 791, "top": 1089, "height": 31, "left": 250}, "words": "预计利奈唑胺不会影响经这些主要细胞色素同工酶代谢的药物的药代动力学。与利奈唑胺联"}, {"probability": {"variance": 0.001896, "average": 0.987079, "min": 0.784744}, "location": {"width": 778, "top": 1119, "height": 31, "left": 248}, "words": "合用药,不会显著改变主要由CYP2C9进行代谢的(8)华法林的药代动力学性质。华法林"}, {"probability": {"variance": 0.000691, "average": 0.992629, "min": 0.839203}, "location": {"width": 687, "top": 1150, "height": 29, "left": 249}, "words": "苯妥因等药物,作为CYP2C9的底物,可与利奈唑胺合用而无须改变给药方案"}, {"probability": {"variance": 0.001373, "average": 0.96458, "min": 0.906998}, "location": {"width": 65, "top": 1185, "height": 25, "left": 250}, "words": "抗生素:"}, {"probability": {"variance": 8.1e-05, "average": 0.995986, "min": 0.956261}, "location": {"width": 664, "top": 1209, "height": 32, "left": 290}, "words": "氨曲南:当二者合用时,利奈唑胺与氨曲南的药代动力学特性均未发生改变"}, {"probability": {"variance": 6.6e-05, "average": 0.996403, "min": 0.952535}, "location": {"width": 704, "top": 1239, "height": 33, "left": 290}, "words": "庆大霉素:当二者合用时,利奈唑胺与庆大霉素的药代动力学特性均未发生改变"}, {"probability": {"variance": 0.000107, "average": 0.995721, "min": 0.948852}, "location": {"width": 752, "top": 1270, "height": 32, "left": 291}, "words": "利福平:在一项对16名健康成人男性志愿者进行的研究中,评价了利福平对利奈唑胺"}, {"probability": {"variance": 0.000186, "average": 0.993553, "min": 0.919788}, "location": {"width": 794, "top": 1301, "height": 31, "left": 251}, "words": "药代动力学影响。研究中志愿者口服利奈唑胺60mg每日2次共5剂,伴或不伴利福平600mg"}, {"probability": {"variance": 0.000113, "average": 0.992124, "min": 0.960945}, "location": {"width": 788, "top": 1332, "height": 29, "left": 250}, "words": "每日1次共8天。利福平和利奈唑胺合用,导致利奈唑胺的Cmax降低21%[90%C"}, {"probability": {"variance": 0.014579, "average": 0.954807, "min": 0.477235}, "location": {"width": 787, "top": 1360, "height": 34, "left": 258}, "words": "5%-27%],AUC0-12降低32%[90%Cl,27%-37%]。这一相互作用的机制未完全阐明,可能"}, {"probability": {"variance": 1.7e-05, "average": 0.997714, "min": 0.982126}, "location": {"width": 491, "top": 1393, "height": 30, "left": 251}, "words": "与肝酶诱导有关。(见【注意事项】中的药物相互作用)"}, {"probability": {"variance": 2.8e-05, "average": 0.99568, "min": 0.982734}, "location": {"width": 187, "top": 1426, "height": 26, "left": 254}, "words": "单胺氧化酶抑制作用"}, {"probability": {"variance": 5.5e-05, "average": 0.995635, "min": 0.962004}, "location": {"width": 756, "top": 1450, "height": 34, "left": 291}, "words": "利奈唑胺为可逆的、非选择性的单胺氧化酶抑制剂。所以,利奈唑胺与肾上腺素能药物"}, {"probability": {"variance": 2.5e-05, "average": 0.994746, "min": 0.985399}, "location": {"width": 142, "top": 1482, "height": 26, "left": 579}, "words": "第13页,共25页"}, {"probability": {"variance": 0.001557, "average": 0.976699, "min": 0.867101}, "location": {"width": 98, "top": 1509, "height": 22, "left": 312}, "words": "No:20130823"}], "language": 3}